Evidence map›Paper›PMID 42333496›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

The Association Between Human Papillomavirus Type 16 E6 Seroprevalence and Degrees of Anal Disease Among Men With HIV: A Nested Case Control Study.

Krystle A Lang Kuhs, Christopher Otieno, Staci Sudenga, Tim Waterboer, Weiqun Tong, Dorothy Wiley, Jay H Bream, Steven Wolinsky, Jeremy Martinson, Gypsyamber D'Souza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Krystle A Lang KuhsDepartment of Epidemiology and Environmental Health, College of Public Health, University of Kentucky, Lexington, KY, USA.ORCID 0000-0002-1351-3927
Christopher OtienoDepartment of Epidemiology and Environmental Health, College of Public Health, University of Kentucky, Lexington, KY, USA.
Staci SudengaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Tim WaterboerDivision of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Weiqun TongDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Dorothy WileySan Francisco School of Medicine, University of California, San Francisco, CA, USA.
Jay H BreamDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Steven WolinskyFeinberg School of Medicine, Northwestern University, Evanston, IL, USA.
Jeremy MartinsonDepartment of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0003-4673-7238
Gypsyamber D'SouzaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionHuman papillomavirus type 16 (HPV16) E6 antibodies may be an early biomarker of anal cancer. We cross-sectionally evaluated when in the course of anal disease, HPV16 antibodies are induced.MethodsA nested case-control study of 846 men who have sex with men (MSM) was conducted within a prospective study of men with and without HIV. Cases of anal HPV16 (N=262), biopsy-confirmed high-grade squamous intraepithelial lesion (HSIL;N=140), and anal cancer (N=21) were individually matched to controls (N=423) on HIV status, study-participation duration, and age. Serum samples closest to diagnosis underwent HPV serologic testing; prediagnostic serial samples were tested for anal cancers only. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs).ResultsHPV16 E6 seroprevalence was non-significantly elevated in anal disease: OR:1.6 (95%CI:0.7-3.6) for HPV16 infection; OR:1.4 (95%CI:0.5-3.8) for HSIL; and OR:1.5 (95%CI:0.3-9.0) for anal cancer. HPV16 E6 seroprevalence was dramatically lower among men with versus without HIV with the same disease stage: 1.5% vs. 11.2% (

Indexed as

Anus NeoplasmsHIV InfectionsHuman papillomavirus 16Oncogene Proteins, ViralPapillomavirus InfectionsRepressor ProteinsAdultAntibodies, ViralCase-Control StudiesCross-Sectional StudiesHomosexuality, MaleHumansMaleMiddle AgedProspective StudiesSeroepidemiologic StudiesAntibodies, ViralE6 protein, Human papillomavirus type 16Oncogene Proteins, ViralRepressor Proteinsanal cancerHIVHPVHPV16 E6 antibodieshuman papillomavirusserology

Identifiers

PMID42333496
PMCPMC13305415

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.